EMILY DRINKWARD: Open Payments
NPI 1770298267 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,723 in 114 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $1,260 · 2025 $3,723
Food & beverage: $3,559Education: $164
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 14 | $847 |
| GlaxoSmithKline, LLC. | 22 | $618 |
| AstraZeneca Pharmaceuticals LP | 15 | $583 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 18 | $552 |
| Grifols USA, LLC | 12 | $252 |
| Insmed, Inc. | 13 | $188 |
| Merck Sharp & Dohme LLC | 4 | $184 |
| Regeneron Healthcare Solutions, Inc. | 3 | $135 |
| Mallinckrodt Hospital Products Inc. | 3 | $106 |
| Verona Pharma, Inc. | 4 | $84 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, Prolastin-C Liquid, OFEV, WINREVAIR, TEZSPIRE, Arikayce.
Industry payments across CA — which companies pay providers there.
